57th ASH Annual Meeting and Exposition (December 5-8, 2015): 711. Cell Collection and Processing: Comparative studies and Novel Agents

Cell Collection and Processing Oral and Poster Abstracts
Oral

Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Moderators:

Anand Padmanabhan, MBBS, MA, PhD, BloodCenter of Wisconsin and Chitra M. Hosing, MD, The University of Texas MD Anderson Cancer Center

Disclosures:

No relevant conflicts of interest to declare.

7:00 AM

511

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

Darja Karpova, PhD^1,2^*, Susanne Brauninger, MD¹^*, Eliza Wiercinska, PhD¹^*, Ariane Kraemer, B.Sc.³^*, Belinda Stock³^*, Jochen Graff, MD⁴^*, Christophe Escot⁵^*, Garry Douglas, PhD⁵^*, Barbara Romagnoli, PhD⁵^*, Eric Chevalier, PhD⁵^*, Klaus Dembowsky, MD, PhD,⁵^*, Leon Hooftman, MD⁵ and Halvard Bonig, MD, MA^1,3,6

¹Institute for Transfusion Medicine/Immunohematology, Goethe University, Frankfurt, Germany
²DOM, WUSTL, Saint Louis, MO
³Institute Frankfurt, German Red Cross Blood Service BaWüHe, Frankfurt, Germany
⁴Clinical Trials Center KSRM, Goethe University, Frankfurt, Germany
⁵Polyphor Ltd., Allschwil, Switzerland
⁶Department of Medicine/Hematology, University of Washington, Seattle, WA

7:15 AM

512

Mobilization of CD8⁺ Central Memory T-Cells with Enhanced Reconstitution Potential in Mice By a Combination of G-CSF and GMI-1271-Mediated E-Selectin Blockade

Ingrid G Winkler, PhD¹^*, Valerie Barbier¹^*, Kristen J Radford, Ph.D.¹^*, Julie M Davies, Ph.D.¹^*, Jean-Pierre Levesque, PhD¹, Theodore A.G. Smith, Ph.D.²^*, William E. Fogler, Ph.D.²^* and John L Magnani, Ph.D.²

¹Mater Medical Research Institute, South Brisbane, Australia
²GlycoMimetics, Inc., Rockville, MD

7:30 AM

513

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Armin Ghobadi, MD^*, Michael P. Rettig, PhD, Matthew Holt^*, Julie Ritchey^*, Linda Eissenberg^* and John F. DiPersio, MD, PhD

Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

7:45 AM

514

Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation

Florent Malard, MD, PhD¹^*, Myriam Labopin, MD²^*, Patrice Chevallier, MD, PhD³^*, Thierry Guillaume, MD, PhD³^*, Alix Duquesne⁴^*, Sophie Derenne⁴^*, Eolia Brissot, MD.PhD⁵^*, Marc Gregoire, PhD⁶^*, Philippe Moreau³^*, Philippe Saas, PhD⁷, Mohamad Mohty, MD, PhD⁵ and Bbéatrice Gaugler, PhD⁸^*

¹Hematology Department, CHU, Nantes, France
²Department of Hematology and Cell Therapy, Saint Antoine Hospital, Paris, France
³Department of Hematology, Nantes University Hospital, Nantes, France
⁴EFS Pays de Loire, Nantes, France
⁵Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
⁶CRCNA, INSERM U892, Nantes, France
⁷EFS BFC, INSERM UMR 1098/Université Bourgogne Franche-Comté/ EFS BFC/LabEx lispSTIC, Besancon, France
⁸CDR Saint-Antoine, UMR 938, Paris, France

8:00 AM

515

A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis

Gayatri Setia, B.S.¹^*, Nabil Hagog, Ph.D.²^*, Bita Jalilizeinali, DNP³^*, Sharon Funkhouser, R.N.³^*, Loretta Pierzchanowski, R.N.³^*, Fengshuo Lan, MD, PhD⁴^*, Theodore G. Gabig, MD³, Bonnie Kiner-Strachan, MD³, Karen Kelleher³^*, Ming-Chu Hsu, PhD⁵^*, Li-Wen Chang⁶^* and Michael W. Schuster, MD⁷

¹Stony Brook University School of Medicine, Stony Brook, NY
²Stony Brook University Hospital, Stony Brook
³Stony Brook University Hospital, Stony Brook, NY
⁴Stony Brook Unversity Hospital, Stony brook, NY
⁵Taigen Biotechnology Co., Ltd., Taipei, Taiwan
⁶Taigen Biotechnology, Taipei, Taiwan
⁷Leukemia, Lymphoma and Transplant Program, Stony Brook University Hospital, Stony Brook, NY

8:15 AM

516

A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma

Mark A Fiala, BS, CCRP¹^*, David Schwab, BA CCRP¹^*, Ravi Vij, MD, MBA¹, Amanda F. Cashen, MD², Keith Stockerl-Goldstein, MD¹ and Camille N. Abboud, MD¹

¹Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
²Washington University School of Medicine, Saint Louis, MO

See more of: Cell Collection and Processing
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

711.O1.6 711. Cell Collection and Processing: Comparative studies and Novel Agents